GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AlloVir Inc (NAS:ALVR) » Definitions » Purchase Of Investment

AlloVir (AlloVir) Purchase Of Investment : $-125.83 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is AlloVir Purchase Of Investment?

AlloVir's purchase of investment for the three months ended in Dec. 2023 was $-9.78 Mil. It means AlloVir spent $9.78 Mil on purchasing investments. AlloVir's purchase of investment for the trailing twelve months (TTM) ended in Dec. 2023 was $-125.83 Mil.

Compared with last quarter ($-101.85 Mil in Sep. 2023 ), AlloVir spent less money on purchasing investments in Dec. 2023 ($-9.78 Mil).


AlloVir Purchase Of Investment Historical Data

The historical data trend for AlloVir's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AlloVir Purchase Of Investment Chart

AlloVir Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Purchase Of Investment
Get a 7-Day Free Trial -119.31 -300.26 -76.59 -228.81 -125.83

AlloVir Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Purchase Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.47 -11.76 -2.44 -101.85 -9.78

AlloVir Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-125.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AlloVir Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of AlloVir's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


AlloVir (AlloVir) Business Description

Traded in Other Exchanges
N/A
Address
1100 Winter Street, Waltham, MA, USA, 02451
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T-cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
Executives
Vikas Sinha director, 10 percent owner, officer: See Remarks C/O ALEXION PHARMACUETICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410
Diana Brainard director C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
Edward Miller officer: General Counsel C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Brett R Hagen officer: Chief Accounting Officer 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Gilead Sciences Inc 10 percent owner 333 LAKESIDE DR, FOSTER CITY CA 94404
Cintia Piccina officer: Chief Commercial Officer 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R
Derek N. Adams director ALLOVIR, INC., 1100 WINTER STREET, WALTHAM MA 02451
Van Beek Jeroen B officer: Chief Commercial Officer C/O TRICIDA, INC., 7000 SHORELINE COURT, SUITE 201, SOUTH SAN FRANCISCO CA 94080
Ercem Atillasoy officer: See Remarks C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
David Hallal director, 10 percent owner, officer: Chief Executive Officer C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
F2 - Tpo Investments Llc director, 10 percent owner C/O SINGER, MCKEON INC., 8 W 38TH ST SUITE 1001, NEW YORK NY 10018
F2 Bioscience Av 2022 Llc director, 10 percent owner 8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
Capital I 2020 F2 director, 10 percent owner 8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
F2 Mc, Llc director, 10 percent owner 8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
Globeways Holdings Ii Ltd director, 10 percent owner C/O SINGER, MCKEON INC., 8 W 38TH ST. STE. 1001, NEW YORK NY 10018

AlloVir (AlloVir) Headlines